RVPH
HEALTHCAREReviva Pharmaceuticals Holdings Inc
Live · NASDAQ · May 9, Close
What's Moving RVPH Today?
No stock-specific AI insight has been generated for RVPH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.88
Fundamentals
Trading
RVPH News
21 articles- UBS Group (RVPH) holds 746,095 shares, a 5.82% stake in RevivaStock Titan·May 7, 2026
- Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric IndicationsYahoo Finance·Apr 23, 2026
- Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress PlansYahoo Finance·Apr 21, 2026
- RVPH: Shareholder Letter Introduces New IPYahoo Finance·Apr 20, 2026
- Reviva Announces Letter to ShareholdersYahoo Finance·Apr 15, 2026
- Does Cobenfy Have the Potential to Become a Top Drug for BMY?Yahoo Finance·Apr 9, 2026
- RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2Yahoo Finance·Apr 1, 2026
- Reviva Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 30, 2026
- Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock SplitYahoo Finance·Mar 25, 2026
- Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingYahoo Finance·Mar 23, 2026
- Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingYahoo Finance·Mar 19, 2026
- Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingYahoo Finance·Mar 18, 2026
- Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026Yahoo Finance·Jan 12, 2026
- Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in SchizophreniaYahoo Finance·Jan 8, 2026
- Reviva to Present at the Sachs 9th Annual Neuroscience Innovation ForumYahoo Finance·Dec 29, 2025
- Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of SchizophreniaYahoo Finance·Dec 23, 2025
- RVPH: Brilaroxazine Poster PresentationsYahoo Finance·Nov 24, 2025
- Reviva Reports Third Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Nov 13, 2025
- Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025Yahoo Finance·Nov 12, 2025
- Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary FibrosisYahoo Finance·Nov 10, 2025
- Reviva to Participate in the Spartan Capital Securities Second Annual Investor ConferenceYahoo Finance·Oct 29, 2025
All 21 articles loaded
Price Data
52-Week Range
$0.88
Fundamentals
Trading
About Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for central nervous system (CNS) disorders and other critical health issues. The company’s lead candidate, RP5063, presents a unique therapeutic strategy for managing schizophrenia and mood disorders, supported by an innovative drug delivery platform that aims to improve treatment efficacy. Reviva is well-positioned for growth in the dynamic mental health sector, with a robust pipeline and a strong focus on addressing significant unmet medical needs as it navigates key clinical development milestones.